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Introductive note
a wide literature on Streptococcus Pneumoniae (Pn) 
infections is available, largely published in the recent 
years, after the introduction of the heptavalent conjugate 
vaccine in uS and in europe. this review is based on 
the most up-to-date scientific articles about this patho-
gen.
Epidemiology of Streptococcus 
Pneumoniae: general features  
and current situation in Italy
Diseases sustained by Streptococcus Pneumoniae ac-
count each year for a heavy burden all over the world, 
especially in the undeveloped Countries, being esti-
mated by World health organization (Who) that 1.6 
million deaths, of which nearly 0.7-1 million in children 
less than 5 year of age, are attributable to this aetiologi-
cal agent [1].
Pn is a gram-positive capsulated diplococcal bacteria, 
widespread in the population, responsible for various 
pathological conditions of significant clinical impor-
tance: invasive Pneumococcal Diseases (iPD), such as 
meningitis and sepsis, Community acquired Pneumonia 
(CaP) and other less important clinical conditions wide-
spread in the population, being the pathogen responsible 
of 1/3 of all cases of acute otitis media (aom) and 
sinusitis in paediatric age and, rarely, of infections 
in bones, joints or soft tissues [2, 3]. the experience 
gained in some european countries has revealed that 
besides meningitis, cases of sepsis and bacteraemic 
pneumonia, in paediatric age, account for the most 
consistent number of cases presenting manifestations 
of pneumococcal infection (reaching 70% of all cases 
of iPD) [4].
the natural and obligate reservoir responsible for the 
infection is man himself who naturally harbours the 
micro-organism in the naso-pharynx, according to a 
dynamic process dependent upon various factors and 
conditions; the state of carrier is, in fact, influenced not 
only by age (with a peak in prevalence in children aged 
< 2 years, thereafter decreasing progressively) [5, 6], but 
also by other factors such as frequenting a group of infants, 
breast feeding, belonging to a large family, use of antibiot-
ics, the season, passive smoking and certain morbid condi-
tions, such as pathological conditions that lead to a deficit 
in immuno-competence or respiratory viral infections [5]. 
Data in the literature concerning the role of risk factors, 
whether of a major or minor nature, in determining iPD 
have been widely discussed: according to some reports, 
the major conditions, such as neoplasias, chronic respira-
tory and circulatory diseases, recognized also for other 
vaccine-preventable diseases (e.g. influenza), have been 
demonstrated to play an important role in the occurrence of 
iPD. in this regard, in one study, approximately 80% of the 
hospitalized cases presented at least one clinical condition 
of associated co-morbidity [7], whilst in another report, 
more than 40% of the cases occurring in children aged 
> 5 years presented at least one of the following clinical 
conditions: hiV infection, congenital immunodeficiency, 
sickle cell anaemia or malignant tumours [8]. at the same 
time, other findings indicate that iPD can occur also in 
healthy subjects, as observed in a study performed on cases 
occurring in paediatric subjects and other age groups, none 
of whom were found to be carriers of any of the above-
mentioned risk conditions [9, 10]. age, therefore, in the 
experience of these authors would, in itself, represent a risk 
factor [11]. more detailed studies need to be focused on 
this latter aspect, in order to optimize vaccine preven-
tion programmes and strategies against Pn in europe, 
where, up until 2003, almost all member Countries had 
decided to adopt selective strategies targeted to subjects 
belonging to risk categories [12].
in europe, the incidence of iPD, varies between approx-
imately 8-25 cases per 100,000 inhabitants (on average 
in uS 23.3/100,000) with wide differences between ge-
ographical areas. nevertheless, the rarely used practice 
of confirmation by means of haemoculture, the frequent 
empirical use of antibiotics, as well as the suboptimal 
sensitivity of the most used laboratory test could lead to 
an under-estimation of the phenomenon.
in italy, the most complete data available concern men-
ingitis, collected by means of a special surveillance net-
work (passive type), which was commenced in 1994 and 
performed in collaboration with the ministry of health, 
regional epidemiological observatories, and the italian 
national health institute (nhi). between 1994-2006, 
overall approximately 3,000 iPD cases were reported in 
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these records, notifications ranging from a minimum of 
108 cases in 1994 to a maximum of 308 in 2003. the 
most frequently identified pathogen, within those pre-
ventable using current available paediatric vaccines, in 
the overall period 1994-2006, was Pn (45.2%), followed 
by Neisseria Meningitidis (42.4%) and Haemophilus 
Influenzae type b (hib) (12.4%): in particular, Pn was 
found to be responsible for approximatively 30% of the 
forms in 1994, with percentages reaching 45% in 2004 
and 55.7% in 2006 (relative increase due, in part, also 
to the simultaneous reduction in the number of cases 
caused by hib) [13].
recent active epidemiological surveillance studies enable 
a better estimation of the burden caused by the iPD in 
italy. in 2002, the nhi launched a Pilot Programme of 
surveillance in two regions, Piemonte and Puglia. the 
results showed that, with a reasonable and methodical use 
of diagnostic updating by blood culture, the incidence of 
the invasive forms reached values of 11.3/100,000 infants 
up to 2 years of age, results which were much higher than 
those previously estimated [14]. other studies performed 
in italy revealed an iPD incidence of 59.2 cases/100,000 
infants < 3 years old [15], and of 47.4/100,000 children 
< 5 years old [16]. Continuation of the two latter inves-
tigations resulted in an even greater incidence, namely 
63.8/100,000 (< 3 years) and 62.0/100,000 (< 5 years). 
other data collected during 2005 from the active lab-sur-
veillance on iPD in Piemonte revealed incidence rates of 
16 and 12/100,000 in infants and in children aged 0-4 
years, respectively [17].
another national investigation, performed as part of 
an active hospital surveillance network, showed that 
the proportion of bacteraemia due to Pn reached 1.2% 
of all the blood cultures performed in children with a 
temperature > 38°C [18]: this value would appear to 
be very significant, particularly if compared with the 
data emerging from the case series in uS, where the 
prevalence was approximately 1.6%. Findings reported 
in italy reveal a similar incidence to those reported by 
other european Countries.
Matching between circulating  
and vaccine serotypes
the seven serotypes (4, 6b, 9V, 14, 18C, 19F and 23F) 
contained in Pneumococcal Conjugate Vaccine (PCV), 
currently available on the market, are those most com-
monly widespread in the Western world, therefore it is 
possible to estimate that the hypothetical protection of the 
preparation is 88.7% in north america and australia and 
77.6% in europe (where there is a significant circulation of 
the 1 and 8 non-Vaccine sero-types - nVt). it is tempting 
to suggest that in africa, latin america and asia, where 
the 1 and 5 serotypes are more prevalent, coverage would 
be 67.3%, 63.4% and 43.1%, respectively [1].
the most recent data available in italy reveal a good 
matching between circulating serotypes responsible for 
iPD and those contained in PCV, particularly under 2 
years of age, where up to 81% of the cases of sepsis ap-
pear to be due to Vaccine sero-types (Vt). this would 
be in keeping with the results from the case series elabo-
rated by the nhi surveillance system, for the period 
1997-1999 [19].
in a more recent italian study, performed during the 
period 1997-2000, typing more than 500 isolates from 
cases of iPD collected by a group of 65 laboratories, it 
was demonstrated that among children, 72% of the iso-
lates belonged to serotypes included in the PCV [20], 
whereas analogous results have been observed in a 1-
year population-based surveillance study, undertaken 
in two italian regions (Piemonte and Puglia) where this 
percentage was approximately 79% in patients under 5 
years of age [21]. 
other studies in italy focusing on the carrier condition in 
paediatric age have shown that the colonizing serotypes, 
thus potentially responsible for the pathological condi-
tions, corresponded to vaccine ones with values ranging 
from 63% to 78%, thus showing that similar differences 
exist in the various studies as far as concerns age of the 
subjects examined, with the percentage of carriers being 
greater in the early years of life [22, 23]. likewise, as far 
as concerns CaP, with the national experience in a group 
of children aged between 2 and 5 years, it was possible to 
estimate the theoretical coverage of PCV as 58% [24]. 
Safety and tolerability of PCV
With regard to the safety, a wide experience of broad 
offer of PCV has been carried out, primarily in uS, 
confirming its excellent profile both when administered 
individually or in association with the other vaccines 
routinely used in infancy [25]. Polivalent conjugate 
vaccines have been tested in a number of clinical trials 
performed in different areas of the world, showing good 
safety and tolerability profiles, even among children 
infected with human immunodeficiency Virus (hiV). 
no significant adverse events have been identified in 
post-marketing surveillance in the uS, where more 
than 20 million children have been immunized [1]. our 
investigations performed in liguria, the first region in 
italy where an universal infant free-immunization pro-
gramme was started since 2003, confirm data regarding 
the safety of the vaccine, when given in co-adminis-
tration with the hexavalent vaccine (DtaP-iPV-hib 
-hepb): no serious adverse events have so far been 
reported, more than 80,000 doses being administered 
in infants (3-5-11 months schedule), with vaccination 
coverages reaching nearly 90% in 2005 [26].
Some authors found a higher reactogenicity, both at a 
local and at a systemic level, after concomitant admin-
istration of PCV with DtaP-iPV-hib-hepb or similar 
formulations in comparison to immunisation with these 
vaccines given alone [27-38]. all things considered, 
PCV displays acceptable side-effects: local reactions 
would, in fact, occur in like manner as found for DtaP 
vaccination (13-18% local reactions) and systemic ef-
fects are similar to those induced by conjugated vaccine 
for hib meningitis (temperature > 38°C: 15-23%).
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Immunogenicity of PCV and currently 
available schedules
Several studies have investigated the immunogenicity 
of PCV, also with the aim of identifying an antibody 
response value correlated with protection towards Pn-
associated disease. Some authors have identified cut-
off values which differed in relation to each vaccine 
serotype, but the way in which these thresholds have 
been calculated would appear somewhat arbitrary. at 
last, using the same model based on the results from the 
northern California Kaiser Permanente (nCKP) study 
in uS, the Who decided to use a single antibody titre 
concentration value of 0.35 µg/ml, to be considered as 
protective against iPD by all the serotypes contained in 
the heptavalent vaccine [27, 39].
a number of trials have also been recently carried out 
both to evaluate the best vaccine schedule and to in-
vestigate the possible immunological interference in 
the response to PCV when administered together with 
other preparations foreseen in infant age. nowadays, a 
general consensus exists with the fact that PCV is higly 
immunogenic, even when co-administered with other 
routine infant vaccines, following different immunisation 
schedules providing 3 priming doses in the first year of 
life and a booster in the second year. immunogenicity of 
PCV has been investigated using both a 2-4-6 months + 
12-15 months schedule, the uS schedule [33, 35, 38, 40], 
and a 2-3-4 months + 12-23 months challenge, as used in 
uK, France and germany [29-31, 34, 41].
a serum titre above the selected cut-off for all Vt 
was reached in 82-100% of the participants, after the 
administration of the third priming dose [29-33, 38]. 
Furthermore, a strong anamnestic response was evident 
following the administration of PCV as the booster dose 
given in the second year of life.
three studies have been conducted in infants in 
which Polysaccharide Pneumococcal Vaccine (PPV) 
was given as a booster (fourth dose) after a priming 
series of three doses with PCV-7 or PncomPC (PCV-
7 with a protein of N. meningitidis as a carrier): PPV 
as booster gave higher antibody concentrations than 
PCV-7 and PncomPC, but not necessarily a higher 
efficacy (only studied for otitis media sustained by 
vaccinal types) [34, 42, 43]. more research has been 
performed in older children on this item, but little 
data on resulting immunogenicity have been published 
as using cut-off levels [41, 44-47].
Studies performed in the Scandinavian countries and 
in italy have demonstrated a good immunogenicity of 
PCV, when administered simultaneously with DtaP-
iPV-hib or DtaP-iPV-hbV-hib vaccines, using a 3-5-
11/12 months (2 + 1) regimen [27, 36]. after the booster 
dose, results for all Vt are substantially superimposable 
to those obtained with vaccination schedules following 
a 3 + 1 regimen. Particularly, it was found that the per-
centage of infants achieving serum titres above the min-
imum cut-off value of 0.35 µg/ml, one month after the 
second dose, was 76-100% for all serotypes contained 
in the vaccine, with the exception of certain serotypes, 
as 6b and 23F, with values ranging from nearly 40% to 
50%, respectively [27, 36]. indeed, a certain number of 
polysaccharide antigens, namely 6b, 23F and 9V, used 
for the preparation of PCV, have demonstrated to be less 
immunogenic after the priming series in different stud-
ies, also using 3 doses in the primary cycle [27, 34-36]. 
nevertheless, for serotypes 6b and 23F, even if initially 
displaying low immunogenicity, it has been found that 
the concentration of antibodies tends to increase consid-
erably after the administration of a booster dose, given 
at 11-12 months. PCV is, thus, able to well stimulate 
immune response also using a two priming vaccination 
series, establishing an adequate immunological memo-
ry, as demonstrated by the elicited anamnestic response. 
this was found not only in healthy children but also 
within pre-term infants, a well known category at risk 
for developing iPD [36].
a spontaneous clinical trial is currently underway at our 
research Centre at the university of genoa, aimed at 
evaluation of the immunogenicity of the hexavalent vac-
cine DtPa-hbV-iPV-hib when administered together 
with PCV, the schedule being 3 doses (3-5-11 months) 
during the first year of life: preliminary results, avail-
able in more than 100 subjects, confirm the absence of 
any immunological interference in terms of antibody 
response vs. all the antigens contained both in the hex-
avalent and in the conjugate pneumococcal vaccine 
(data under publishing) [26].
in conclusion, currently available data on immunogenic-
ity of PCV suggest that the use of a vaccine schedule 
with three doses (2 + 1), delaying the booster dose at 
least 6 months after the priming series, may represent a 
valid and practical option for the primary prevention of 
the disease sustained by Pn: this strategy offers benefit 
in terms of protection and compliance to vaccination, 
but also under an economic point of view, as well as 
considering organizational aspects within the health-
care services [36].
intriguingly, post-marketing surveillance data performed 
in uS suggest that even when only two doses of vaccine 
were given in the primary schedule (2-4 months), chil-
dren resulted protected against pneumococcal disease, 
albeit further information need to be obtained concern-
ing the duration of this protection [48].
Direct and indirect effects of PCV
Data related to the effects of PCV in the prevention 
of iPD refer primarily to the uS experience, where a 
strategy of universal immunisation has been ongoing 
since 2000.
a large number of papers have been published in the 
literature during the last years demonstrating both ef-
ficacy (randomized clinical trials) and effectiveness 
(population-based surveillance studies) of PCV against 
iPD, CaP and aom.
the first large randomized, double blind, trial was per-
formed in uS at 23 medical centers within northern 
California Kaiser Permanente (nCKP) [33]. nearly 
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38,000 healthy children were randomized 1:1 to receive 
either the PCV and the meningococcal conjugate type C 
vaccine, at 2-4-6 and 12-15 months of age. Per-protocol 
and intention-to-treat analysis revealed a PCV efficacy 
against invasive disease of 97.4% and 93.9%, respec-
tively.
Subsequent evaluation on the impact of the universal 
vaccination programme with PCV was performed in a 
postlicensure surveillance within the Kaiser Permanente 
population, in children aged < 5 years, monitoring the 
incidence of iPD in a period ranging from 1996 to 2001: 
in this large field study it was immediately shown a 
reduction of Pn-disease of 87% and 58% in infants and 
in 0-2-year-old subjects, respectively, with incidence 
rate caused by Vt felling from 51.5-98.2 to 9.4 cas-
es/100,000 in < 1 year-old children and from 81.7-113.8 
to 38 cases/100,000 in children < 2 years [49].
as shown in table i, numerous population-based sur-
veys have confirmed the high effectiveness of the vac-
cine in preventing Pn-invasive disease [8, 9, 49, 50-54]. 
the last up date on the effectiveness of the PCV, used 
in uS under a universal children immunisation strategy, 
has been recently reported by Centre for Disease Control 
and Prevention (CDC) [55]: data indicate that overall 
iPD rates among children aged < 5 years in 2005 were 
77% lower compared with the years preceding vaccine 
introduction (1998-1999). at the same time, incidence 
of invasive diseases sustained by Vt has decreased by 
98%. globally, an estimated 13,000 cases of iPD were 
prevented in uS children < 5 years during 2005.
additional positive effects of the universal vaccina-
tion programme, not expected at the time when it was 
launched, have gradually emerged: in fact, a significant 
decrease in the incidence of iPD was also reported even 
in unimmunised individuals in the population (indirect 
effect); this phenomenon resulted notable both in chil-
dren too young to have completed vaccination course, 
such as those 0-90 days of age (overall iPD reduction = 
40%) [56], and in adults and elderly, particularly those 
aged over 50 years [51, 53, 54, 57-59]. this was prob-
ably due to the reduction in the circulation of Pn in the 
community, and, consequently, to the decrease in the 
proportion of carriers within the population. one of the 
first studies published on this respect, comparing data of 
iPD incidence in 1998 and in 2001, observed a decrease 
of 32%, 8% and 18% in subjects aged 20-39 years (from 
11.2/100,000 cases in 1998 to 7.6/100,000 in 2001), 40-
64 years (from 21.5/100,000 cases to 19.7/100,000) and 
> 65 years (from 60.1/100,000 cases to 49.5/100,000), 
respectively [51]. main results on the effects of PCV in 
adults and elderly are briefly reported in table ii.
From these reports, it clearly emerges that the most 
important overall benefits, gained from the universal 
vaccination programme, were thanks to the prevention 
of iPD within the population not undergoing vaccina-
tion: according to Who, till 68% of the global benefits 
obtained with the universal campaign in uS was attrib-
utable to the indirect effect, thanks to herd immunity 
[1, 60]. these results undoubtely confirm the dramatic 
decrease in the circulation within the community of the 
Pn-Vt, due to the reduction in the prevalence of na-
sopharyngeal carriage among the immunized population 
(herd immunity effect) [61-65].
moreover, the finding that showed a non-significant 
reduction in circulation of the 16 serotypes not included 
in the PCV, but present in the PPV, actively offered  in 
the uS to elderly > 65 years for several years, demon-
strates that data emerging from this age group after the 
introduction of the universal campaign are clearly to be 
attributed exclusively to PCV. 
Some problems, however, still remain to be considered. 
in fact, since 2003, as many as 30% of the iPD in adults 
> 65 years of age continued to be caused to the Vt and 
fewer than 20% in children < 5 years old in uS [60]. 
Furthermore, individuals with certain co-morbid con-
ditions might benefit less than healthier subjects from 
the indirect effects of the conjugate vaccine: this has 
been observed in older adults and in subjects with as-
sociated co-morbid conditions, whether primitively im-
muno-compromised (i.e. hiV infection) or not (i.e. renal 
failure, heart failure, lung disease) [60, 66]. this would 
appear to indicate that the direct protection of adults with 
Tab. I. reduction rate (%) of ipd, overall and by vaccinal serotypes, by age-class, in children after the introduction of pcv.
References < 1 year < 2 yrs 2-4 yrs < 3 yrs < 5 yrs
Total VT Total VT Total VT Total VT Total VT
hsu K et al. [8] _ _ _ _ _ _ _ _ 69 88
haddy et al. [9] _ _ 66.6 _ 91.9 _ _ _ _ _
Black S et al. [49] _ 87.3 _ 58.1 _ _ _ _ _ 62.4
Kaplan Sl et al. [50] _ _ 66 77 _ _ _ _ _ _
Whitney cg et al. [51] _ _ 69 78 _ _ 44 _ 59 _
herz am et al. [52] _ _ _ _ _ _ 84 _ _ _
Shafinoori et al. [53] _ _ 68 _ 70 _ _ _ _ _
Black S et al. [54] 98.7 100.0 90.9 100.0 _ _ _ _ 84.1 98.8
cdc [55] 77 98 _ _ _ _ _ _ 77 98
vt = vaccine types
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PCV could be very useful in determining an even greater 
protection as far as concerns these morbid forms [60]. it 
is plausible to believe that, in the next future, PCV will 
gradually take the place of the PPV, which could be 
used for a single re-immunization in certain risk-groups, 
this also due both to the gradual hypo-stimulation of the 
humoral response elicited by non-conjugated vaccine in 
subjects to whom repeated doses are administered and to 
the increase in side effect rate after repeated immunisa-
tions with PPV [66].
also with regard to CaP, recent evidences have dem-
onstrated the positive effect of the PCV when used 
under a universal immunisation strategy. Some of the 
most interesting results on these item are summarised 
in table iii.
Since the measurement of vaccine efficacy against con-
firmed pneumococcal pneumonia is constrained by the 
lack of a sensitive and specific method for establishing 
aetiology in cases of non-bacteraemic pneumonia, most 
studies have focused on measuring the overall effective-
ness of the vaccine in preventing radiologically defined 
pneumonia irrespective of aetiology, following guide-
lines introduced by the Who in 2001 for the radiologi-
cal diagnosis [67-71]. initially, the Kaiser Permanente 
Study demonstrated a 20.5% (95% Ci = 4.4-34.0) effec-
tiveness against clinical pneumonia with “positive film” 
(infiltrates beyond the peri-hilar area, consolidation or 
empyema). however, in that investigation, the effec-
tiveness against all types of clinical pneumonia resulted 
not statistically significant (4.3%; 95% Ci = 3.5-11.5). 
in that experience, the radiological diagnosis was per-
formed according to routine practice by the radiologists, 
on duty at the hospital in which the child was seen for 
clinically diagnosed pneumonia: the protective efficacy 
against radiologically confirmed all-cause pneumonia 
was 17.7% [68]. in a more recent investigation, gri-
jalva et al., by means on analysis and comparison of the 
discharge charts collected from approximately 20% of 
Tab. II. reduction rate (%) of ipd, overall and by vaccinal serotypes, by age-class, in adults and elderly not vaccinated (herd effect), after 
introduction of pcv.
References Age group
(years)
Overall IPD
(%)
IPD by VT
(%)
Whitney et al. [51] 20-39
40-64
> 65
32
8
18
_
_
_
Shafinoori et al. [53] 18-49
> 64
42
30
_
_
Black et al. [54] 5-19
20-39
40-59
> 60
18
58
15
14
_
_
_
_
lexau et al. [57] > 50
50-64
65-74
75-84
> 85
28
17
29
35
28
55
_
_
_
_
mcBean et al. [58] 65-74
75-84
> 85
28
31
32
_
_
_
moore et al. [59] 50-64
65-79
> 80
_
_
_
64
74
77
ipd = invasive pneumococcal diseases; vt = vaccine types
Tab. III. efficacy* and effectiveness of pcv against community acquired pneumonia (cap) in children.
References Clinically diagnosed
CAP (%)
Radiologically confirmed
CAP (%)
Pneumococcal
CAP (%)
cutts et al.* [67] 7 37 _
Black et al. [68] 4.3 20.5 90
Klugman et al.* [69] _ 25 _
hansen et al. [70] _ 30.3 _
puumalainen et al. [71] _ 22.9 _
grijalva et al. [72] 39 _ 65
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the uS hospitals, observed a considerable drop in the 
number of hospitalisations for pneumonia in the period 
from 1997 to 2004: at the end of the study period, all-
cause pneumonia admission rates showed a significant 
reduction by 39% (95% Ci = 22-52) in children aged 
< 2 years, with an annual decline of 506 per 100,000, 
representing about 41,000 prevented cases in 2004. in 
particular, during the 8 study years, the reduction in the 
rate of pneumonia, coded as having Pn-disease, resulted 
of 65% (95% Ci = 47-77) [72]. two large clinical trials, 
recently performed in South africa and gambia among 
young children, with a 9-valent PCV, demonstrated a 
vaccine efficacy against pneumonia of 25% and 37%, 
respectively, using the Who criteria for the radiological 
diagnosis [67, 69]. Furthermore, in a recent uS post-
marketing surveillance study, a significant reduction in 
CaP rates was also seen in 0-2 year-olds, in 2003-2004, 
compared with earlier periods [73]. Preliminary data 
on the effects of the PCV in liguria, italy, a region 
where a universal immunisation strategy for all infants 
was started since 2003, emerged from a research, under 
publishing, financed by the italian ministry of research 
and the university and coordinated by our Center: as de-
rived from the analysis of the hospital Discharge Charts 
in this region, a significant reduction in the hospitalisa-
tion rates for pneumonia, both pneumococcal and over-
all, and for aom was registered in children aged 0-24 
months, comparing pre (2000-2002) vs. post-vaccina-
tion (2003-2005) periods (data under publishing) [26].
as far as concerns aom, PCV has demonstrated to 
confer a “modest” protection. this is what resulted in 
one of the first controlled randomized trials (Finom) 
investigating this item, in which PCV-7 was given to 
infants, following a 2-4-6 and 12-month schedule [32]. 
this study was carried out testing biological specimens 
obtained from children in whom tympanocentesis had 
been performed: the per-protocol efficacy of PCV-7 for 
clinically diagnosed aom, caused by Vt, was found to 
be 57% (95% Ci = 44-67%), but due to observed partial 
replacement of Vt, the overall efficacy of the vaccine 
in this study was finally estimated to be 34% (95% Ci = 
21-45%), yet. this study was too small to demonstrate 
overall efficacy considering all-cause aom as outcome 
(Ve = 6% with 95% Ci = 4-16). these results confirm 
those previously published by black et al. in the origi-
nal nCKP study, where a PCV efficacy of 66.7% (p = 
0.035) and of 7% (95% Ci = 4.1-9.7) was found against 
episodes of clinically diagnosed aom, due to Vt and 
by all pathogens, respectively [33]. in the nCKP study, 
protection against the placement of tympanostomy tubes 
resulted 20.1% (95% Ci = 1.5-35.2) and 20.3% (95% Ci 
= 3.6-34.1) in the per-protocol and in the intention-to-
treat analysis, results much higher than that observed in 
the Finom study. a number of papers, both randomized 
clinical trials and field epidemiological investigations, 
have studied efficacy and effectiveness of PCV against 
aom within the pediatric population (tab. iV) [2, 39, 
40, 42, 55, 74-80]. in particular, grijalva et al. compared 
rates of outpatients visits, using the national ambula-
tory and hospital medical Care Survey in uS, before 
(1994-1999) and after (2002-2003) the introduction of 
PCV: aom visit rates showed a 20% decline in children 
aged < 2 years [76]. this rate is in keeping with findings 
emerging from clinical trials in which a 9-valent Pn-
conjugate vaccine was investigated, showing a vaccine 
efficacy of 17% against all-cause aom, in israeli chil-
dren aged 1-3 years: furthermore, a good coverage from 
this vaccine just against the antibiotic-resistant strains, 
responsible for aom, was supposed [81]. otitis media, 
indeed, represents one of the principal indications for 
antibiotic treatment, thus contributing to a large extent 
to the onset of antibiotic-resistance [76]: also consider-
ing this, since otitis media is a considerable cause of 
morbidity among the paediatric population, as stated by 
Who, the cited “modest” effect of PCV finally results 
in a significant global benefit [1].
Other effects of PCV on replacement and 
pattern of antibiotic-resistance
attention has been focused, over the last few years, 
on some reported negative effects associated with the 
extended use of PCV, likely, paradoxically, to nullify, 
in the very near future, all that has been achieved to 
date: which means the risk of new serotypes, also cause 
Tab. IV. efficacy* and effectiveness of pcv against aom in children.
References Overall (%) Vaccine
serotypes (%)
Cross-reactive
serotypes (%)
Preventing tympanostomy
tube placement (%)
eskola et al. (Finom) * [32] 34 57 51 4
Black et al. (ncKp)* [33] 8.9 66.7 _ 20.1
prymula et al. [39] 33.6 57.6 65.5 _
Fireman et al. (ncKp follow-up)* 7.8 _ _ 24
grijalva et al. [76] 20 _ _ _
esposito et al. [77] 6-9 50-60 _ _
palmu et al. (Finom follow-up)* 8 _ _ 44
dagan et al. [79] 17 _ _ _
poehling et al. [80] 28 _ _ 23
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of iPD, replacing those currently contained in the vac-
cine and the selection, thus the increase, of antibiotic-
resistant strains. replacement is a phenomenon mainly 
dependent on secular trends, within the natural ecology 
of Pn: even if it was previously reported also in areas 
where PCV was not part of the immunisation schedule, 
recently, after the introduction of the vaccine within the 
universal immunisation programmes, it has been sug-
gested it might be caused by the reduction in the preva-
lence of people colonized with Vt and by the possible 
substitution of these latter with other nVt [82].
a number of clinical trials have investigated this 
item, with discordant results: in the Finom trial, an 
increase in aom sustained by nVt had been de-
scribed in children vaccinated with PCV: this event 
occurred 27% more in the immunised than in the 
control group [32, 42]. the nCKP study and another 
research by Prymula et al. failed to confirm this evi-
dence for both PCV and PCV-11, yet [33, 39]. at the 
same time, another clinical trial in children aged 1-7 
years, vaccinated with PCV, found no substitution of 
Vt by other pathogens in middle ear fluid collected 
during the first episodes of aom [45].
During the last years, the incidence of iPD cases, sus-
tained by serotypes present and not in the PCV, has 
been largely monitored within well structured lab-based 
surveillance systems in different countries. like this, in 
some populations, as subjects < 5 years and adults > 40 
years, it has been shown that the reduction in iPD caused 
by Vt was associated with a parallel increase in cases 
by nVt strains [60]. in a study carried out in uS, within 
a surveillance network in eight paediatric hospitals, the 
isolates of nVt 15 and 33 were found to be increased in 
the post-vaccination phase [50]. likewise, surveillance 
data in uS from 1994 to 2004 confirmed this behaviour, 
comparing nVt 15 and 33 with serotypes 1 and 3, used 
in this comparison because they represented, in the pre-
vaccination era, the principal serotypes causing iPD 
amongst those not included in the PCV [83]. another 
reported nVt causing iPD, important as far as concerns 
the phenomenon of replacement, is 19a, as revealed 
from the microbiological surveillance data of the Active 
Bacterial Core System in uS, in the period 1996-2004, 
when incidence rates by this type increased from 2 to 
8.3/100,000, in children under 2 years of age [61, 48]. 
the most recent data by the CDC show that, although 
iPD caused by Vt declined through 2005, overall iPD 
rates leveled off beginning in 2002, primarily because of 
increases in the incidence of iPD caused by nVt 19a: 
among children aged < 5 years, the incidence of iPD by 
this serotype increased from 2.6 cases in 1998-1999 to 
9.3 cases per 100,000 in 2005, the largest reported in-
crease for any one serotype. in 2005, 40% of the 1,200 
additional cases of nVt-iPD among children aged < 5 
years was caused just by serotype 19a [55].
even if it is, obviously, advisable to continue to monitor 
this event, the most recent data, emerging from the men-
tioned population-based surveys, show that the overall 
magnitude of the phenomenon is small compared with 
the reduction in disease sustained by Vt, as already 
fully discussed [8, 60]. on the other hand, there can 
be no doubt that more widespread protection than that 
available with PCV-7 would be welcome: several clini-
cal trials are currently underway, aimed at evaluation of 
new pneumococcal vaccines, even conjugated with dif-
ferent proteic carriers, with a larger spectrum of action 
than PCV-7, containing up to 9, 10, 11 and 13 antigens 
of the micro-organism (tab. V) [62, 67, 84-88].
as far as concerns the effect of universal vaccination on 
antibiotic resistance pattern, it has been shown that, fol-
lowing the introduction of PCV universal programme, 
an overall reduction in the resistance to the most fre-
quently used antibiotics occurred: this is what appeared 
in 2002, within a surveillance network, activated in 
1993-1994, in eight uS hospital, monitoring iPD in the 
paediatric age [50]: the proportion of isolates resist-
ant to penicillin has decreased by almot 50%, the first 
time such a decrease in resistance has been noted since 
surveillance began. this is not surprising considering 
that the resistance of Pn to antibiotics is a phenomenon 
more frequently observed for the serotypes that cause 
iPD and, therefore, identifiable particularly with those 
included in the vaccine. likewise, the same surveillance 
activity reported the proportion of nVt isolates not 
susceptible to penicillin as increased during the study 
period: only a slight trend towards an increase in the 
years 2001 and 2002 compared to 2000 was registered, 
yet, the phenomenon resulting, on the whole, an event 
of little clinical importance [50]. results confirming 
the significant positive effect of the wide use of PCV 
on the pattern of antibiotic resistance clearly emerged 
from another lab-based survey by the active bacterial 
Core System in uS: in infants < 2 years, the incidence 
of resistance to penicillin, as far as concerns the micro-
organism causing iPD, showed a dramatic 81% drop, 
from 70.3/100,000 in 1999 to 13.1/100,000 in 2004. at 
the same time, this phenomenon was observed also in 
adults, a non-immunised population, who thus, in this 
respect, benefited also from the above mentioned herd 
immunity effect [61].
to summarize, in the period immediately following the 
introduction of routine immunisation with PCV in uS, 
it became immediately evident that iPD occurring in 
children < 2 years, the target of the programme, were 
always less frequently sustained by Pn-strains resistant 
to penicillin, cefotaxime or erythromycin. nevertheless, 
as from 2002, this phenomenon involved also children 
aged > 2 years, later also involving a group of more 
elderly subjects, with a reduction in the resistance to 
penicillin observed also in subjects > 65 years of age. 
it is tempting to suggest that this was due primarily to 
a reduced colonization by the Pn-serotypes included in 
the PCV, which, harbouring usually in the naso-pharynx 
of children, are also able to select resistant strains under 
the pressure exerted by eventual antibiotic treatment. 
albeit, this theory was not found to be valid for the 
6a and 19a serotypes, for which sensitivity to chemo-
antibiotics still remains substantially unchanged, thus 
confirming the limited impact of vaccination on the 
naso-pharyngeal colonization by these two strains [66].
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Cross protection of PCV vs. non-vaccine 
serotypes
in respect with cross-protection, various studies have 
demonstrated a direct protective effect of PCV towards 
iPD sustained by the nVt 6a, a polymer of a tetrasac-
charide repeating unit, which differs in a single linkage 
from the tetrasaccharide of 6b [68, 89]. this same phe-
nomenon has not been demonstrated for other nVt, in 
particular 19a, even if the vaccine contains a serotype, 
namely 19F, which is substantially similar [50, 90]: this 
lack of cross-protection is indirectly confirmed by the 
increase in the iPD sustained by serotype 19a in chil-
dren < 5 years and in the elderly. We believe this find-
ing should be taken into due consideration, particularly 
bearing in mind the fact that currently this serotype is 
the most common cause of iPD in uS [55, 91]. Fur-
thermore, 19a has been demonstrated to be resistant to 
various antibiotics [48].
moreover, even when cross-protection has been ob-
served in clinical trials, as in the case of the 6a serotype, 
the post-marketing studies failed to reveal any reduction 
effect on naso-pharyngeal carriage [82, 92]. in parallel 
with these findings, the cases of iPD sustained by the 
6a serotype revealed a significant reduction only in 
subjects < 5 years, but not in the rest of the population, 
thus suggesting that a cross-protection alone is unable to 
generate an indirect protective effect [89].
in the light of the results obtained, the authors sug-
gest that, since cross-protection is lacking against some 
nVt, despite being characterized by an important clini-
cal impact, future vaccine formulations should include 
also the latter and, in particular, 19a [48].
Economic analysis of the universal infant 
immunisation programmes with PCV: 
implications for Italy
Despite the scientific solidity demonstrating the broad 
effectiveness of the universal infant vaccination pro-
grammes with PCV, documented worldwide and espe-
cially in uS, the introduction in europe of the vaccine, 
licensed since 2001, into the national immunisation 
schedules has been delayed in several countries (Fig. 1), 
mainly due to financial considerations, strictly linked to 
the cost per dose, higher, on average, than that of the oth-
er routinary used vaccines. a number of papers from uS, 
Canada, australia and europe has been published in the 
last years focusing the economic evaluation of the PCV 
used under a universal immunisation strategy [93-103].
a very interesting systematic review on this item, 
considering the main researches published between 
2002 and 2005, has been recently done by beutels et 
al [104]: despite evaluated studies on Cost-efficacy 
analysis (Cea) and Cost-utility analyis (Cua) had 
used a similar methodology of analysis, on a markov 
model, the calculated incremental Cost-effictiveness 
ratios (iCer) differed greatly between experiences, 
being sometimes favourable sometimes the opposite. 
this etherogeneous scenario could, at least in part, de-
pend by the different basic assumptions inserted in the 
used model of analysis, namely (i) the incidence and the 
burden of the Pn-associated diseases, with consequent 
direct and indirect costs, (ii) the price of the vaccine 
itself and of the whole immunisation programme (lo-
gistic and organisational aspects) and (iii) the estimated 
vaccine efficacy. moreover, most of these researches 
considered immunisation programmes structured on a 
4-dose schedule (3 + 1), with the only exception of two 
studies, in which a regimen of 3-doses (2 + 1), admis-
tered to children during the first year of life, had been 
evaluated: this last strategy is currently adopted in the 
Scandinavian countries and in some italian regions. but 
the main bias of nearly all the studies published in the 
mentioned period was that only direct effects, those ob-
tained among vaccinated children, had been considered 
in the economic analysis of the immunisation campaign: 
the positive indirect effects among not immunised popu-
lation, deriving from the herd immunity and the reduc-
tion in antibiotic resistance, as largely discussed before, 
had not been taken into right account, thus neglecting a 
significant part of the overall benefit of the immunisa-
tion programme. introducing the herd immunity effect in 
the epidemiological model of analysis of any economic 
study evaluating programmes of universal immunisa-
Tab. V. composition of 7-pcv and other innovative polivalent-wide-spectrum pneumococcal conjugate vaccines under study (from lockart 
et al., 2006 [66], mod.).
Vaccine abbreviation Carrier protein Pneumococcal serotypes
7vpnc crm197 4, 6B, 9v, 14, 18c, 19F, 23F
7vpnc-omp meningococcal omp 4, 6B, 9v, 14, 18c, 19F, 23F
9vpnc crm197 1, 4, 5, 6B, 9v, 14, 18c, 19F, 23F
9vpnc-mncc crm197 1, 4, 5, 6B, 9v, 14, 18c, 19F, 23F
10vpnc-pd-dit pd, diphtheria and tetanus toxoids 1, 4, 5, 6B, 7F, 9v, 14, 18c, 19F, 23F
11vpnc-dt diphtheria and tetanus toxoids 1, 3, 4, 5, 6B, 7F, 9v, 14, 18c, 19F, 23F
11vpnc-pd non-typable haemophilus influenzae pd 1, 3, 4, 5, 6B, 7F, 9v, 14, 18c, 19F, 23F
13vpnc crm197 1, 3, 4, 5, 6a, 6B, 7F, 9v, 14, 18c, 19a, 19F, 23F
crm: cross-reactive material; omp: outer membrane protein; pd: protein d
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tion with PCV need to be considered as mandatory: 
only using such an approach it is possible to give policy 
makers a real picture of the overall financial benefits 
of the preventive strategy, thus orienting interventions 
in the area of Public health under a rational approach, 
balancing available resources and health priorities. this 
has also been clearly demonstrated by the most recent 
publications on this item from Canada, uK, uS and the 
netherlands [60, 102, 105-109]: these experiences have 
concluded that if both the herd immunity effect and the 
reduction in the strains resistant to penicillin are consid-
ered, the iCer of universal immunisation programmes 
is seen to be highly favourable and even cost-saving. 
this is what results also in a study performed in nor-
way, where a financial cut-off of euro 54,000 per life 
Year gained (lYg) was set by the government for the 
implementation of any health-care intervention. in fact, 
assuming that three vaccine doses could provide the 
same protection as four, considering the effect of herd 
immunity and both direct and indirect costs in the eco-
nomic analysis of the universal immunisation strategy of 
all new borns, authors found that the programme would 
have resulted cost-saving: just in consideration of these 
results, the PCV was officially recommended starting in 
2005 into national schedule in this country [109].
on the basis of the above described experiences in eu-
ropean countries where a universal strategy with PCV 
has been adopted and considering that the epidemio-
logical scenario of the diseases sustained by Pn in these 
geographycal areas is nearly superimposable to that 
existing in italy, we support an active, free-of-charge, 3 
dose-schedule (2 + 1) programme for the immunisation 
of all italian children during the first year of life, as the 
best strategy both under the health care and the financial 
point of view.
Conclusive remarks
recent evidences reported in our paper, showing the 
direct and indirect protection afforded by PCV-7 when 
used under a universal children immunisation strategy, 
clearly suggest the need to adopt this preventive tool 
in both developed and under developing countries, as 
recently stated in a position paper by the Who. in uS 
especially iPD and CaP showed a significant decrease 
since 2000, when the vaccine was first introduced on 
the market. analogue results have been registered in 
respect with antibiotic non-susceptible pneumococcal 
infections. a positive effect, even if less evident, was 
also observed with respect to aom. Currently, nor the 
replacement and the increase in antibiotic non-suscepti-
ble strains not included in the vaccine seemed to be able 
to alter the cited overall benefits: the possibile avail-
ability of new conjugated vaccines, with an extended 
serotype coverage, is welcome yet, particularly in the 
Fig. 1. european recommendations for use of pcv in children and mode of payment: up-date to February 2008 (data kindly provided by 
Weyth vaccines italy).
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view of the lack of cross-protection by currently avail-
able vaccine against type 19a and 6a, with its implica-
tion on herd immunity. in any case, continue monitoring 
the mid-term potential negative impact of the routinary 
extended use of the PCV among chidren need to be con-
sidered a public health priority in the next years for all 
countries which decide to adopt universal immunisation 
programmes.
to date, the introduction of the PCV in italy for routine 
national vaccination of all newborns seem to be fully 
justified by both the epidemiological scenario and the 
estimated predicted efficacy of the vaccine vs. the local 
circulating serotypes: co-administering the PCV with 
the currently recommended hexavalent vaccine (DtPa-
PiV-hbV-hib), using a 3-dose schedule in the first year 
of life, has to be considered the most efficient strategy, 
balancing the need of protection against the Pn-associ-
ated diseases and both the economic and organizational 
aspects of the programme, thus its mid-term sustain-
ability.
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